1h Free Analyst Time
The influenza vaccine market is forecasted to grow by USD 3.76 billion during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. The report on the influenza vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence and incidence of influenza, rising awareness about influenza vaccination, and initiation of immunization programs and research activities.
The influenza vaccine market is segmented as below:
By Distribution Channel
- Hospitals and pharmacies
- Government and institutional
- Others
By Type
- Live attenuated influenza vaccines
- Recombinant influenza vaccines
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the influenza vaccine market covers the following areas:
- Influenza vaccine market sizing
- Influenza vaccine market forecast
- Influenza vaccine market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global influenza vaccine market: Altimmune Inc., AstraZeneca Plc, Baxter International Inc., BioDiem Ltd., BiondVax Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., FluGen Inc., GlaxoSmithKline Plc, Mitsubishi Chemical Group Corp., Novavax Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Shijiazhuang Yiling Pharmaceutical Co Ltd., SK Chemicals Co. Ltd., Vaccitech Plc, Vaxart Inc., and Vaxine Pty Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is need for revaccination."
According to the report, one of the major drivers for this market is the increasing prevalence and incidence of influenza.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Altimmune Inc.
- AstraZeneca Plc
- Baxter International Inc.
- BioDiem Ltd.
- BiondVax Pharmaceuticals Ltd.
- CSL Ltd.
- Emergent BioSolutions Inc.
- F. Hoffmann La Roche Ltd.
- FluGen Inc.
- GlaxoSmithKline Plc
- Mitsubishi Chemical Group Corp.
- Novavax Inc.
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Sanofi SA
- Shijiazhuang Yiling Pharmaceutical Co Ltd.
- SK Chemicals Co. Ltd.
- Vaccitech Plc
- Vaxart Inc.
- Vaxine Pty Ltd.
